US Bancorp’s Soleno Therapeutics SLNO Stock Holding History

US Bancorp’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,339	Closed	-$44.8K	–	4324
2026 Q1	$44.8K	Sell	1,339 -4	-0.3%	-$157	﹤0.01%	2760
2025 Q4	$62.2K	Sell	1,343 -934	-41%	-$51.2K	﹤0.01%	2599
2025 Q3	$154K	Buy	2,277 +1,311	+136%	+$97.2K	﹤0.01%	2136
2025 Q2	$80.9K	Buy	966 +228	+31%	+$17.1K	﹤0.01%	2543
2025 Q1	$52.7K	Sell	738 -10	-1%	-$487	﹤0.01%	2718
2024 Q4	$33.6K	Buy	+748	New	+$38.8K	﹤0.01%	2927

US Bancorp's SLNO Position: Q2 2026 in Review

US Bancorp sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,339 shares — an estimated $44.8K sold.

US Bancorp first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $154K in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

US Bancorp reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 1,339 Soleno Therapeutics shares in Q2 2026, an estimated $44.8K.
US Bancorp first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
US Bancorp's Soleno Therapeutics position peaked at $154K in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.